Skip to main content
. 2021 May 8;11(10):3220–3230. doi: 10.1016/j.apsb.2021.04.020

Figure 5.

Figure 5

(A) In vitro antifungal effect of free AmB, BSA NP/AmB, BSA MP/AmB and BSA MTN/AmB.Data are presented as mean ± SD (n = 3). (B) Survival rate of mice bearing C. neoformans after different treatments. ∗∗∗P < 0.001. (C) Colony-forming units (CFU) on Days 3 and 7 in the lungs of infected mouse models. Data are presented as mean ± SD (n = 3). ∗∗P < 0.01. (D) In vivo assessment by MRI of infection signals after different treatments. The infected part of the lungs is highlighted by a red rectangle. (E) PAS-stained slides prepared from cross-sections of lungs at Day 10 post-infection and observed by light microscopy. Cryptococci are indicated by black arrows (scale bar = 50 μm). (F) In vivo therapeutic effects of BSA NP/AmB, BSA MP/AmB, and BSA MTN/AmB treatments on intracellular C. neoformans. C. neoformans are shown in red due to RFP fluorescence (scale bar = 10 μm).